At the University of Tokyo, scientists have turned stem cells into a working model of the human intestine — and through it, found that a compound long hidden in black licorice may hold new promise for the millions living with inflammatory bowel disease. Glycyrrhizin, drawn from a plant root with centuries of medicinal history, emerged from a screen of 3,500 candidates as a meaningful reducer of intestinal inflammation, performing well in both lab tissue and living mice. The finding matters not only for what it might offer IBD patients whose current treatments fall short, but for what it reveal
ScienceDaily
· May 10, 2026
· health
· 2 min read
High
Sourcing: Verified
Black licorice compound shows promise in IBD treatment discovery
IBD affects approximately 4 million people worldwide with chronic symptoms including diarrhea, abdominal pain, and fatigue that significantly impact daily life.
◉
Health & Medicine
8252 related articles
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% match
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% match
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% match
Related Coverage
World Socialist Web Site · Aug 22
H5N1 avian flu spreads across Australia with 290 confirmed infections
Australia faces a rapidly spreading H5N1 avian flu outbreak with 290 confirmed infections across all states, threatening…
Devdiscourse · Aug 22 Congo's Bundibugyo Crisis: Health Attacks Threaten Economic Stability Beyond Medical ResponseWHO warns that violence and attacks on health facilities in eastern DRC's Bundibugyo outbreak threaten disease control a…
The Times of India · Aug 22 Reactor blast at Telangana pharma unit kills 2, injures 9A reactor blast at a pharmaceutical unit in Telangana's Yadadri Bhuvanagiri district killed two workers and injured nine…
Google News · Aug 22 Exercise-mimicking weight-loss pill clears first human trialsEnveda's ENV-308, a novel obesity drug designed to replicate exercise's biochemical effects, has successfully completed …
Bias & Framing
⚖
Article presents promising IBD research with straightforward scientific reporting, minimal bias detected in presentation of stem cell study findings and glycyrrhizin results.
Bias Direction
center
Confidence
HIGH
Standard scientific discovery narrative emphasizing research methodology, problem-solution structure, and incremental progress toward medical treatment.
shows promise
emerges as a top candidate
strongest performers
Limitations or caveats of the research (gap between lab models and human trials)
Timeline for potential clinical application
Cost or accessibility considerations for future treatment
Perspectives from IBD patient advocacy groups
Competing or alternative treatment approaches in development
Potential side effects or safety concerns of glycyrrhizin
Geopolitical Impact
🌎
Medical research on black licorice compound for IBD treatment has no direct geopolitical implications; purely scientific discovery with potential global health benefits.
Escalation Risk
low
Confidence
HIGH
Economic Lens
📈
Black licorice compound glycyrrhizin shows promise as IBD treatment, potentially creating new pharmaceutical market opportunities and reducing healthcare costs for 4M+ patients globally.
Market Signal
bullish
Confidence
MED
Pharmaceutical and biotechnology
Healthcare and medical devices
Natural products and nutraceuticals
Agricultural (licorice cultivation)
Potential new treatment option for IBD patients could reduce symptom burden, improve quality of life, and lower out-of-pocket costs if glycyrrhizin-based therapies prove cost-effective compared to existing immunosuppressants and biologics.
FDA approval pathway for novel IBD therapeutic could accelerate; potential regulatory framework for natural compound-derived pharmaceuticals; healthcare reimbursement discussions for new treatment class; possible agricultural subsidies for medicinal licorice production.